Entera Bio Ltd. (ENTX) stock
ENTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$3.11−0.11 (-3.42%)
Close on Nov 13, 2026Market cap $538.47MP/E –Yield –
Entera Bio cash
Cash and short-term investments held at the end of each period.
Entera Bio's cash was $265.88M at Sep 30, 2026. For fiscal 2025 it was $7.11M, down 18.7% from the year before. Over ten years it grew 19.4% a year on average. The highest annual figure on record is $24.96M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.11M | -18.7% |
| FY2024 | Dec 31, 2024 | $8.74M | -21.2% |
| FY2023 | Dec 31, 2023 | $11.09M | -10.4% |
| FY2022 | Dec 31, 2022 | $12.38M | -50.4% |
| FY2021 | Dec 31, 2021 | $24.96M | +188.2% |
| FY2020 | Dec 31, 2020 | $8.66M | -43.1% |
| FY2019 | Dec 31, 2019 | $15.22M | +102.8% |
| FY2018 | Dec 31, 2018 | $7.51M | -36.1% |
| FY2017 | Dec 31, 2017 | $11.75M | +182.2% |
| FY2016 | Dec 31, 2016 | $4.16M | +245.5% |
| FY2015 | Dec 31, 2015 | $1.21M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $265.88M | +3001.0% |
| Q2 FY2026 | Jun 30, 2026 | $11.31M | +4.2% |
| Q1 FY2026 | Mar 31, 2026 | $4.14M | -67.1% |
| Q4 FY2025 | Dec 31, 2025 | $7.11M | -18.7% |
| Q3 FY2025 | Sep 30, 2025 | $8.57M | +24.0% |
| Q2 FY2025 | Jun 30, 2025 | $10.86M | +19.9% |
| Q1 FY2025 | Mar 31, 2025 | $12.57M | +36.8% |
| Q4 FY2024 | Dec 31, 2024 | $8.74M | -21.2% |
| Q3 FY2024 | Sep 30, 2024 | $6.92M | -8.8% |
| Q2 FY2024 | Jun 30, 2024 | $9.06M | -0.9% |
| Q1 FY2024 | Mar 31, 2024 | $9.19M | -14.0% |
| Q4 FY2023 | Dec 31, 2023 | $11.09M | -10.4% |
| Q3 FY2023 | Sep 30, 2023 | $7.59M | -47.0% |
| Q2 FY2023 | Jun 30, 2023 | $9.14M | -47.1% |
| Q1 FY2023 | Mar 31, 2023 | $10.69M | -46.8% |
| Q4 FY2022 | Dec 31, 2022 | $12.38M | -50.4% |
| Q3 FY2022 | Sep 30, 2022 | $14.32M | -47.7% |
| Q2 FY2022 | Jun 30, 2022 | $17.28M | -35.8% |
| Q1 FY2022 | Mar 31, 2022 | $20.11M | +22.8% |
| Q4 FY2021 | Dec 31, 2021 | $24.96M | +188.2% |
| Q3 FY2021 | Sep 30, 2021 | $27.40M | +180.5% |
| Q2 FY2021 | Jun 30, 2021 | $26.93M | +76.9% |
| Q1 FY2021 | Mar 31, 2021 | $16.38M | +121.8% |
| Q4 FY2020 | Dec 31, 2020 | $8.66M | +15.4% |
| Q2 FY2020 | Jun 30, 2020 | $9.77M | -16.8% |
| Q4 FY2019 | Dec 31, 2019 | $15.22M | +265.6% |
| Q2 FY2019 | Jun 30, 2019 | $7.39M | +512.9% |
| Q4 FY2018 | Dec 31, 2018 | $7.51M | – |
| Q4 FY2017 | Dec 31, 2017 | $11.75M | – |
| Q4 FY2016 | Dec 31, 2016 | $4.16M | – |
| Q4 FY2015 | Dec 31, 2015 | $1.21M | – |
See a number that looks wrong?